Waters raises guidance as organic growth strengthens and MOBILion expands its technology platform

Organic growth drives a higher 2026 outlook

Waters Corporation (NYSE:WAT) raised every component of its 2026 guidance after organic revenue growth accelerated in the third quarter, providing a stronger operating signal beneath the large acquisition-driven increase in reported sales. Revenue reached US$1.767 billion for the quarter ended October 3, ahead of the company’s guidance midpoint by US$14 million, while organic revenue grew 9% as reported and 10% in constant currency.

Adjusted diluted earnings per share rose 21% year on year to US$4.10, exceeding guidance. Waters now expects full-year reported revenue of US$6.479 billion to US$6.497 billion, lifting the midpoint by US$43 million, and adjusted EPS of US$14.60 to US$14.70. Its forecast for fourth-quarter organic constant currency growth is 7% to 9%, with total revenue expected between US$1.801 billion and US$1.819 billion.

Instruments and consumables lead the underlying performance

The quarter’s organic performance was led by the Analytical Sciences Division, where revenue increased 8% on a reported basis to US$703 million and 9% in constant currency. Instrument revenue grew 10% in constant currency, while chemistry consumables rose 12%. Waters said LC-MS instrument growth reached double digits in constant currency, citing instrument replacement demand and activity linked to GLP-1 medicines, PFAS testing and Indian generics.

Consumables also provided momentum elsewhere in the portfolio. Biosciences reagents grew at a high-single-digit rate on a prior-year comparable basis, representing a 400-basis-point acceleration in year-on-year growth, with both research and clinical reagents contributing. Microbiology in Advanced Diagnostics grew at a mid-single-digit rate on the same comparable basis. Those measures include an estimated prior-year comparison for the businesses acquired from Becton, Dickinson and Company, so they are more informative than the headline reported growth, which is heavily shaped by the acquisition.

Acquisition accounting obscures GAAP earnings

The statutory numbers tell a more complicated story. GAAP diluted EPS was US$0.82, down from US$2.50 a year earlier, while nine-month GAAP results showed a net loss of US$127 million. Waters attributed the pressure to acquisition-related purchase accounting, amortisation, acquisition costs and restructuring charges. In the quarter, purchased intangible amortisation and acquisition-related inventory and fixed-asset fair-value step-ups added US$323 million to the reconciliation between GAAP and adjusted operating income.

The acquisition has also transformed the balance sheet. At October 3, cash stood at US$593 million, against US$5.133 billion of notes payable and debt, while goodwill had risen to US$9.369 billion and net intangible assets to US$8.275 billion. Operating cash flow was US$98 million for the quarter and adjusted free cash flow was US$68 million, figures that sit alongside ongoing integration and financing demands.

MOBILion adds a proteomics technology bet

Alongside the results, Waters announced the acquisition of MOBILion Systems, a developer of SLIM high-resolution ion mobility separation technology. The system separates molecules by size, shape and charge in milliseconds, and Waters said the deal is intended to complement its mass spectrometry portfolio and broaden its entry into proteomics. The release did not disclose the purchase price, consideration or expected financial contribution.

Management is due to outline its starting 2027 growth framework, including the expected contribution from reshoring, synergies and AI-related demand drivers. The immediate test is whether the newly raised 2026 targets can be delivered while the company absorbs a large acquired platform, carries substantially higher debt and turns the promised technology and cost synergies into repeatable cash generation.